245 related articles for article (PubMed ID: 33881621)
1. The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia.
Strauss GP; Macdonald KI; Ruiz I; Raugh IM; Bartolomeo LA; James SH
Eur Arch Psychiatry Clin Neurosci; 2022 Feb; 272(1):17-27. PubMed ID: 33881621
[TBL] [Abstract][Full Text] [Related]
2. Environmental factors contributing to negative symptoms in youth at clinical high risk for psychosis and outpatients with schizophrenia.
Strauss GP
Soc Psychiatry Psychiatr Epidemiol; 2024 Jul; 59(7):1167-1175. PubMed ID: 37624464
[TBL] [Abstract][Full Text] [Related]
3. Negative Symptom Inventory-Self-Report (NSI-SR): Initial development and validation.
Raugh IM; Luther L; Bartolomeo LA; Gupta T; Ristanovic I; Pelletier-Baldelli A; Mittal VA; Walker EF; Strauss GP
Schizophr Res; 2023 Jun; 256():79-87. PubMed ID: 37172500
[TBL] [Abstract][Full Text] [Related]
4. Negative symptoms in bipolar disorder and schizophrenia: A psychometric evaluation of the brief negative symptom scale across diagnostic categories.
Strauss GP; Vertinski M; Vogel SJ; Ringdahl EN; Allen DN
Schizophr Res; 2016 Feb; 170(2-3):285-9. PubMed ID: 26742510
[TBL] [Abstract][Full Text] [Related]
5. Network Analysis Reveals Which Negative Symptom Domains Are Most Central in Schizophrenia vs Bipolar Disorder.
Strauss GP; Esfahlani FZ; Kirkpatrick B; Allen DN; Gold JM; Visser KF; Sayama H
Schizophr Bull; 2019 Oct; 45(6):1319-1330. PubMed ID: 30649527
[TBL] [Abstract][Full Text] [Related]
6. Negative symptoms in schizophrenia differ across environmental contexts in daily life.
Luther L; Raugh IM; Collins DE; Knippenberg AR; Strauss GP
J Psychiatr Res; 2023 May; 161():10-18. PubMed ID: 36893666
[TBL] [Abstract][Full Text] [Related]
7. Defeatist performance beliefs in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia.
Clay KB; Raugh IM; Bartolomeo LA; Strauss GP
Early Interv Psychiatry; 2021 Aug; 15(4):865-873. PubMed ID: 32743974
[TBL] [Abstract][Full Text] [Related]
8. Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia.
Strauss GP; Esfahlani FZ; Galderisi S; Mucci A; Rossi A; Bucci P; Rocca P; Maj M; Kirkpatrick B; Ruiz I; Sayama H
Schizophr Bull; 2019 Sep; 45(5):1033-1041. PubMed ID: 30256991
[TBL] [Abstract][Full Text] [Related]
9. The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains.
Chang WC; Strauss GP; Ahmed AO; Wong SCY; Chan JKN; Lee EHM; Chan SKW; Hui CLM; James SH; Chapman HC; Chen EYH
Schizophr Bull; 2021 Mar; 47(2):386-394. PubMed ID: 32909606
[TBL] [Abstract][Full Text] [Related]
10. Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.
Gupta T; Cowan HR; Strauss GP; Walker EF; Mittal VA
Schizophr Bull; 2021 Jan; 47(1):54-63. PubMed ID: 32955097
[TBL] [Abstract][Full Text] [Related]
11. A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.
Strauss GP; Pelletier-Baldelli A; Visser KF; Walker EF; Mittal VA
Schizophr Res; 2020 Aug; 222():104-112. PubMed ID: 32522469
[TBL] [Abstract][Full Text] [Related]
12. Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment.
Kaiser S; Lyne J; Agartz I; Clarke M; Mørch-Johnsen L; Faerden A
Schizophr Res; 2017 Aug; 186():39-45. PubMed ID: 27453425
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of the Negative Symptom Inventory-Psychosis Risk.
Strauss GP; Walker EF; Pelletier-Baldelli A; Carter NT; Ellman LM; Schiffman J; Luther L; James SH; Berglund AM; Gupta T; Ristanovic I; Mittal VA
Schizophr Bull; 2023 Sep; 49(5):1205-1216. PubMed ID: 37186040
[TBL] [Abstract][Full Text] [Related]
14. Reduced DNA Methylation of the Oxytocin Receptor Gene Is Associated With Anhedonia-Asociality in Women With Recent-Onset Schizophrenia and Ultra-high Risk for Psychosis.
Bang M; Kang JI; Kim SJ; Park JY; Kim KR; Lee SY; Park K; Lee E; Lee SK; An SK
Schizophr Bull; 2019 Oct; 45(6):1279-1290. PubMed ID: 31220321
[TBL] [Abstract][Full Text] [Related]
15. Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study.
Giordano GM; Koenig T; Mucci A; Vignapiano A; Amodio A; Di Lorenzo G; Siracusano A; Bellomo A; Altamura M; Monteleone P; Pompili M; Galderisi S; Maj M;
Neuroimage Clin; 2018; 20():627-636. PubMed ID: 30202724
[TBL] [Abstract][Full Text] [Related]
16. Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS.
Hoşgelen EI; Alptekin K
Turk Psikiyatri Derg; 2021; 32(3):219-221. PubMed ID: 34637131
[TBL] [Abstract][Full Text] [Related]
17. Delay discounting in youth at clinical high-risk for psychosis and adults with schizophrenia.
Bartolomeo LA; Chapman HC; Raugh IM; Strauss GP
Psychol Med; 2021 Aug; 51(11):1898-1905. PubMed ID: 32248851
[TBL] [Abstract][Full Text] [Related]
18. Geolocation as a Digital Phenotyping Measure of Negative Symptoms and Functional Outcome.
Raugh IM; James SH; Gonzalez CM; Chapman HC; Cohen AS; Kirkpatrick B; Strauss GP
Schizophr Bull; 2020 Dec; 46(6):1596-1607. PubMed ID: 32851401
[TBL] [Abstract][Full Text] [Related]
19. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
[TBL] [Abstract][Full Text] [Related]
20. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders.
Guessoum SB; Le Strat Y; Dubertret C; Mallet J
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109862. PubMed ID: 31927053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
